Keyword: Neil Woodford

Woodford cut down as fund chopped and burned

by Ben Adams

Tuesday, October 15, 2019

After being hailed as a near mystic when it came to stock picks, Britain’s once great oak has been cut down to a sapling as Neil Woodford gets the ax.

Circassia

by Amirah Al Idrus

When it went public in 2014, Circassia was to be the herald of a renaissance for U.K. biotech IPOs. Instead, its pipeline of allergy treatments failed one by one, leading the Oxford-based company to ax all of them and eventually delist from the London Stock Exchange.

Autolus drags on Arix after weak period for CAR-T player

by Nick Paul Taylor

Wednesday, August 28, 2019

Arix reported a 15% drop in its net asset value as a result of the fast-falling share price of the troubled British biotech.

Suspension of Woodford fund set to continue until December

by Nick Paul Taylor

Tuesday, July 30, 2019

News of the suspension extension emerged shorty after Woodford Patient Capital Trust said it is considering a change of management.

Woodford suspends trading in flagship fund after investors flee

by Nick Paul Taylor

Tuesday, June 4, 2019

The surge in outflows follows poor performance by the Neil Woodford's flagship fund that culminated in it being among the worst performers in May.

IPO bonanza continues with $150M listing for Autolus

by Phil Taylor

Friday, June 22, 2018

Biotech IPOs continue to come thick and fast this week, with CAR-T specialist Autolus the latest to list with an impressive $150 million raise.

BenevolentAI bags $115M to fuel AI-enabled R&D push

by Nick Paul Taylor

Friday, April 20, 2018

The round moves the total raised by the company past the $200 million mark and values it at around $2 billion.

Next-gen CAR-T firm Autolus takes funding tally to $173M

by Phil Taylor

Tuesday, September 26, 2017

CAR-T player Autolus has raised $80 million in a third-round financing that it says will fund proof-of-concept testing for three programs.

EuroBiotech Report—Idorsia, Bavarian Nordic, Woodford and more

by Nick Paul Taylor

Thursday, June 22, 2017

In this week's EuroBiotech Report, J&J spins out Idorsia, Bavarian Nordic delays data, Woodford backs dementia fund and more.

Woodford invests in Big Pharma-backed dementia fund

by Nick Paul Taylor

Monday, June 19, 2017

Neil Woodford has invested in the Big Pharma-backed Dementia Discovery Fund.

GET THE NEWSLETTER

Subscribe to FierceBiotech to get industry news and updates delivered to your inbox.